Healthcare AI has to prove it in the workflow | Dr. AJ Blood
Thursday, October 15, 2026
Transcript intelligence
What OpenRounds heard
Source-grounded signals extracted from the episode transcript. Timestamps and supporting excerpts appear when available.
The speaker reports that their JAMA-published study showed an 84% increase in clinical trial enrollment (nearly doubling) with a p-value of 0.04, indicating statistical significance.
The speaker reports that unstructured data in electronic health records often hides critical patient information needed to determine qualification for medications or procedures, requiring manual chart review to uncover relevant history.
The speaker reports that Rectifier assesses patient eligibility for clinical trials by analyzing structured and unstructured EHR data against protocol criteria and provides evidence for its decisions.
Send us Fan Mail (https://www.buzzsprout.com/2550733/fan_mail/new) Dr. Alexander “AJ” Blood is a cardiologist and co-founder and CEO of AIwithCare. He joins Chris Hutchins to discuss trial screening, clinical evidence and the workflow conditions that make AI useful. AJ describes the work behind AI-assisted trial prescreening and the importance of keeping eligibility decisions with people. The discussion connects study results to implementation, monitoring, clinical buy-in and measurable pilot decisions. ## Chapters 00:00:00,000 Welcome to The Signal Room 00:00:05,000 Beneath the Signal 00:00:19,084 Evidence over promises 00:00:41,627 From clinical research to implementation 00:03:42,158 Why effective care struggles to reach patients 00:09:04,840 AI-assisted chart review 00:12:28,992 Who gets access to clinical trials? 00:16:55,393 Building and testing the screening tool 00:23:10,866 What the evidence shows 00:27:35,323 Faster enrollment and shorter timelines 00:30:51,749 Monitoring bias across sites 00:34:57,979 Workflow determines adoption 00:42:41,634 Set clear measures for a pilot 00:47:25,967 Design beside the people doing the work 00:51:46,858 Connect with AJ 00:52:15,636 Closing ## Guest resources - [AJ Blood](https://www.linkedin.com/in/alexander-blood-md-msc-facc-abom-a8654a23/) - [Guest website](https://aiwithcare.com/) Study context: the 2025 JAMA prescreening trial reported 35 enrollments with AI assistance versus 19 with manual screening. Enrollment was exploratory; the primary outcome was time to eligibility determination. This was a single-center heart-failure trial use case. These findings do not establish an 84% enrollment gain for other settings. [2025 JAMA study](https://jamanetwork.com/journals/jama/fullarticle/2830514) · [2024 NEJM AI study](https://ai.nejm.org/doi/full/10.1056/AIoa2400181) Support the show (https://www.buzzsprout.com/2550733/support) About The Signal Room: The Signal Room is a podcast and communications platform exploring leadership, ethics, and innovation in healthcare and artificial intelligence. Hosted by Christopher Hutchins, Founder and CEO of Hutchins Data Strategy Consultants. Leadership, ethics, and innovation, amplified. Website: https://www.hutchinsdatastrategy.com/ LinkedIn: https://www.linkedin.com/in/chutchins-healthcare/ YouTube: https://www.youtube.com/@ChrisHutchinsAi Book Chris to speak: https://www.chrisjhutchins.com/
Show transcript excerpt
Send us Fan MailDr. Alexander “AJ” Blood is a cardiologist and co-founder and CEO of AIwithCare. He joins Chris Hutchins to discuss trial screening, clinical evidence and the workflow conditions that make AI useful. AJ describes the work behind AI-assisted trial prescreening and the importance of keeping eligibility decisions with people. The discussion connects study results to implementation, monitoring, clinical buy-in and measurable pilot decisions. ## Chapters 00:00:00,000 Welcome to The Signal Room 00:00:05,000 Beneath the Signal 00:00:19,084 Evidence over promises 00:00:41,627 From clinical research to implementation 00:03:42,158 Why effective care struggles to reach patients 00:09:04,840 AI-assisted chart review 00:12:28,992 Who gets access to clinical trials? 00:16:55,393 Building and testing the screening tool 00:23:10,866 What the evidence shows 00:27:35,323 Faster enrollment and shorter timelines 00:30:51,749 Monitoring bias across sites 00:34:57,979 Workflow determines adoption 00:42:41,634 Set clear measures for a pilot 00:47:25,967 Design beside the people doing the work 00:51:46,858 Connect with AJ 00:52:15,636 Closing ## Guest resources - [AJ Blood](https://www.linkedin.com/in/alexander-blood-md-msc-facc-abom-a8654a23/) - [Guest website](https://aiwithcare.com/) Study context: the 2025 JAMA prescreening trial reported 35 enrollments with AI assistance versus 19 with manual screening. Enrollment was exploratory; the primary outcome was time to eligibility determination. This was a single-center heart-failure trial use case. These findings do not establish an 84% enrollment gain for other settings. [2025 JAMA study](https://jamanetwork.com/journals/jama/fullarticle/2830514) · [2024 NEJM AI study](https://ai.nejm.org/doi/full/10.1056/AIoa2400181)Support the showAbout The Signal Room: The Signal Room is a podcast and communications platform exploring leadership, ethics, and innovation in healthcare and artificial intelligence. Hosted by Christopher Hutchins, Founder and CEO of Hutchins Data Strategy Consultants. Leadership, ethics, and innovation, amplified.Website: https://www.hutchinsdatastrategy.com LinkedIn: https://www.linkedin.com/in/chutchins-healthcare/ YouTube: https://www.youtube.com/@ChrisHutchinsAiBook Chris to speak: https://www.chrisjhutchins.com
Daily healthcare AI brief
Get the free healthcare AI briefing
One concise briefing built from reporting, research, policy, blogs, videos, and full podcast transcripts.
Free. Get a sign-in link by email to finish subscribing. An account is created if needed. Unsubscribe anytime. Already subscribed? Sign in to save and personalize.